GLP-1 and Depression: What the FDA Found
In 2023, the FDA opened a formal investigation into whether GLP-1 medications cause suicidal thoughts. The investigation has continued through subsequent updates, and the relationship is still not fully settled. Here is what is actually known — and what to do if you are struggling.
This is an article about an uncomfortable topic, and we are going to be careful with it. If you are reading this because something feels off — flatter, heavier, less hopeful than usual — you are not alone, and you are not making it up. Depression is one of the most consistently mentioned off-label experiences in GLP-1 patient communities. It is also one of the hardest to pin down clinically.
What the trials and regulators have said so far is more cautious than what you may see in headlines. The FDA-approved labels for Wegovy, Ozempic, Mounjaro, and Zepbound do not list depression as a recognized adverse reaction. Large randomized trials, including the cardiovascular outcome trials for semaglutide, have not shown a statistically significant increase in depression or suicidality compared to placebo. But post-marketing reports, observational data, and a clear biological plausibility have all kept the question open.
The honest version of the answer is this: depression on GLP-1s is real for some people, but the causal relationship between the medication and the mood change has not been established. Several things change at once when you start the drug, and any of them can drive a depressive shift on its own.
What's actually happening
The FDA launched its review of suicidal ideation reports in July 2023, after European regulators flagged a small number of post-marketing cases. The agency reviewed clinical trial data, post-marketing reports, and meta-analyses. In January 2024, the FDA stated that its preliminary evaluation did not find evidence that GLP-1 receptor agonist use causes suicidal thoughts or actions. The investigation has continued as a routine pharmacovigilance activity, and the agency continues to recommend that clinicians and patients monitor for mood changes.
Several large observational studies have come to similar conclusions. A widely-cited analysis in JAMA Internal Medicine using a real-world cohort found no increased risk of suicidal ideation among semaglutide users compared to controls — and in some analyses, a slightly lower risk, possibly reflecting the mood benefits of weight loss and metabolic improvement.
That does not mean nothing is happening to anyone. It means that when you average across hundreds of thousands of patients, the medication does not appear to systematically push people toward depression or suicidal thoughts. The experience of individuals can still diverge from the average. People do report new or worsening depression on GLP-1s, and that experience deserves to be taken seriously even when the population-level signal is null.
What the research shows
The biological story is mixed. GLP-1 receptors exist in brain regions involved in mood, including the hippocampus and prefrontal cortex. Some animal studies suggest GLP-1 signaling has antidepressant-like effects. Other studies show GLP-1 activation can blunt reward responses, which could in principle contribute to anhedonia — the inability to feel pleasure, which is a core feature of depression. Both directions have plausibility, and neither is dominant in the human evidence.
The non-pharmacological drivers are probably more important for most people. Rapid caloric restriction is a known trigger for depression. Eating 1,000 calories a day, even without trying, deprives the brain of nutrients and steady glucose. Rapid weight loss disrupts identity in ways that can be destabilizing, especially for people whose relationship to food and body has been complicated for a long time. Social dynamics shift — comments from others, changes in clothing, changes in how partners and family relate to you — and not all of those changes feel good. Sleep often fragments, especially early on, and disrupted sleep is one of the most reliable triggers of depressive symptoms.
There is also the quiet possibility that GLP-1s reveal pre-existing depression that food was masking. If you were using eating to regulate mood — and many people are, often without realizing it — taking that tool away can let underlying depression become visible for the first time. That is not the drug causing depression; it is the drug uncovering something that was already there. The treatment is the same either way: it deserves real help.
If this is hitting you
Talk to your prescriber first
Do not stop the medication suddenly without a conversation. Mood changes are worth raising directly, and there are options — slower titration, lower dose, or temporary hold — short of discontinuation.
Get a real evaluation
Depression is treatable whether or not the GLP-1 caused it. A primary care doctor, therapist, or psychiatrist can help you separate medication side effects from a depressive episode that needs its own treatment.
Check the basics
Severe caloric restriction, fragmented sleep, and isolated meals all worsen mood on their own. Hitting protein and calorie targets and keeping daily movement and social contact protect against medication-attributed lows.
Common questions
Common Concerns
Did the FDA find that GLP-1s cause depression?expand_more
Is depression listed on the label?expand_more
Why do people report depression if the trials did not show it?expand_more
Should I stop my GLP-1 if I feel depressed?expand_more
What if I am having thoughts of self-harm?expand_more
Keep exploring
Browse all GLP-1 guides, or read about other reported side effects.